CMPS's next COMP360 durability disclosure moves the psychedelic basket ≥8% intraday.

Predicted 2026-08-30 · Resolves 2026-12-01 · markets · Global

62%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

Compass Pathways is testing a psilocybin-based treatment called COMP360 for people with hard-to-treat depression. When Compass releases new data about how long the treatment's benefits last — or whether patients relapse — it tends to send not just Compass's stock but the entire psychedelic medicine sector swinging sharply. This prediction says that swing will be at least 8% up or down on the day the news drops.

Resolution rule: YES if Compass Pathways (CMPS) issues a COMP360 durability/relapse data disclosure on or before 2026-12-01 AND CMPS closes ≥8% up or down (absolute) versus prior close on the disclosure day. Source: Compass Pathways IR/press releases and Nasdaq closing price for CMPS. Check date: 2026-12-01. Resolves NO if no such disclosure occurs by the date.

CMPS is the sector's de-risking bellwether; the TRD relapse/durability data is the catalyst institutions are positioned around. Correlated peers (MNMD, ATAI, GH Research) move on CMPS binary events.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →